Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453 alone and with PDR001 in advanced solid tumors
NL-OMON53097Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sabatolimab and spartalizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and melanoma, sponsored by Novartis. Primary endpoints: Safety, Tolerability and 2 more. Started Feb 2016; status: active, not recruiting.
02
Drugs
sabatolimabspartalizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NL-OMON53097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53097.